Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

By C. Chu, V. Cheng, I. Hung, M. Wong, K. Chan, K. Chan, R. Kao, L. Poon, C. L. Wong, Y. Guan and 2 more. Thorax, 2004

1,614 citations recorded by the source corpus.

Subfields: Genetics, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/b7b9c87f1dcc51e092e95fb8cbb8bd2878c678f1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Wan Zhu
2. Xiangqian Guo
3. Longxiang Xie
4. E. Keyaerts
5. L. Vijgen
6. Piet Maes

In Infectious Diseases

1. Kwok-Yung Yuen
2. Patrick C. Y. Woo
3. Susanna K. P. Lau
4. J. Chan
5. K. To
6. V. Cheng
7. Kwok-Hung Chan
8. S. Navas-Martín

Citations in the corpus

• The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status (2020, background): “Based on virus genome sequencing results and evolutionary analysis, bat has been suspected as natural host of virus origin, and SARSCoV-2 might be transmitted from bats via unknown intermediate hosts to infect humans.”
• Long-term psychiatric morbidities among SARS survivors (2009, background): “Patients were confronted with a highly contagious novel virus that required compulsory isolation treatment and administration of experimental drugs [39].”
• In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine (2004, background): “Protease inhibitors (lopinavir/ritonavir) in combination with ribavirin may be of benefit as antiviral therapy, when given in the early phase of the illness [8, 9] .”
• Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model (2020, neutral): “(30) may support this decision (30) .”
• Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro (2020, background): “Antiviral compounds previously reported to show effect against SARS-CoV or other coronaviruses may be effective against SARS-CoV-2 (Chu et al., 2004; de Wilde et al., 2014; Dyall et al., 2014; Shen et al., 2019; Cao et al., 2015).”
• SARS and MERS: recent insights into emerging coronaviruses (2016, positive): “The protease inhibitors lopinavir and ritonavir, which are used in combination to treat infection with HIV, improved the outcome of patients with SARS when combined with ribavirin, compared with patients who were treated with ribavirin alone 106,107 .”
• SARS: Systematic Review of Treatment Effects (2006, background): “When LPV/r was added as an initial treatment to ribavirin and corticosteroid therapy, the death rate was lower than among those who received ribavirin and corticosteroids (1/ [20] .”
• SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far (2020, background): “In previous betacoronavirus epidemics, several antiviral drugs, such as ribavirin, interferon, lopinavir-ritonavir, and darunavir/cobicistat (prezcobix) were tested, with some showing promising in vitro results [53].”
• Virology, Epidemiology, Pathogenesis, and Control of COVID-19 (2020, background): “It has been reported that the use of lopinavir/ritonavir with ribavirin has a good therapeutic effect in SARS [70] and MERS [71].”